ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
13 oct. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network
08 sept. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
06 sept. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
18 août 2022 05h18 HE
|
ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
22 juil. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
21 juil. 2022 05h21 HE
|
ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
21 juin 2022 11h45 HE
|
ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
15 juin 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...